Not Another
Minute^®

In a clinical study of 547 patients considered to be clinically low risk (T1N0), Breast Cancer Index identified ~25% as likely to benefit from extended endocrine therapy and high risk of late distant recurrence.¹

In a clinical validation of 402 patients with node-positive disease (N1, 1-3 positive nodes) who are often considered to be high risk and candidates for extended endocrine therapy, Breast Cancer Index identified 22% as having limited risk of late distant recurrence, and 69% of those were not likely to benefit from endocrine therapy beyond 5 years.²